FATE compared with ADCT: revenue, margins and what each company keeps, and the suppliers and customers both name

FATEFate Therapeutics Inc

Mkt capRevenueRevenue

ADCTADC Therapeutics SA

Mkt capRevenueRevenue

Compare

FATEFate Therapeutics Inc

ADCTADC Therapeutics SA

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

FATE

0 of 3at or beyond implied

Reportimpliedrealized× implied

Q3 FY26—▼−11.48%—

Q2 FY26±20.5%▼−7.35%×0.36

May 13 '26±57.5%▼−5.11%×0.09

Q1 FY26±21.3%▲+5.41%×0.25

ADCT

0 of 2at or beyond implied

Reportimpliedrealized× implied

Nov 5 '26—▼−4.65%—

Oct 13 '26—▼−8.60%—

= impliedFATE realized, solidADCT realized, hatchedOne scale, both sides: full bar = 91%× = |realized| ÷ impliedSource: market data

Q2 FY26

±90.3%

▼−14.63%

×0.16

May 4 '26±23.0%▼−3.92%×0.17

FATEFate Therapeutics Inc

1.85▼−0.03%· post 1.82

Mkt cap$223.1MRevenue$2MQ2 FY26Revenue$7MFY25

ADCTADC Therapeutics SA

1.58▼−3.66%· post 1.58

ClosedNov 6 '26

Mkt cap$201.7MRevenue$19MQ2 FY26Revenue$71MFY24

Compare

ClosedNov 6 '26

FATEFate Therapeutics Inc

ADCTADC Therapeutics SA

1.85▼−0.03%post 1.82

Price

1.58▼−3.66%post 1.58

$223.1M

Mkt cap

$201.7M

Q2 FY26$2M

Revenue

$19MQ2 FY26

FY25$7M

Revenue

$71MFY24

FATE1.85▼−0.03%vsADCT1.58▼−3.66%ClosedNov 6 '26